
Married couple battling concurrent stage IV CRC diagnoses speaks at Denver Bash

The average odds of getting colorectal cancer in your lifetime are 1 in 24.
The average odds of getting it before you turn 45 are 1 in 240.
But, as Erik Stanley shared with Blue Hope Bash Denver guests this weekend, the odds of a married couple under 45 — who grew up 1,000 miles apart and without any genetic predisposition — both being diagnosed with stage IV colon cancer within two years are about 1 in 100 million.
That’s exactly what Erik and his wife, Kacie Peters, are facing today.
“Since our diagnoses, we’ve done over 100 hours of chemotherapy, had a dozen surgeries with more to come, and spent at least 65 nights away from home in the hospital,” Kacie told Bash guests.
“And we’ve done it all so that our 5-year-old son doesn’t have to grow up without us,” Erik added.
Kacie and Erik are extraordinary. Despite dual, concurrent diagnoses with stage IV colorectal cancer, they have risen to the challenges posed by this disease and continue to be incredible parents, accomplished professionals, and now, outspoken advocates for colorectal cancer.
They spoke at the Blue Hope Bash Denver on October 1 to encourage support for the Alliance’s mission and raise funds to research new treatments and find a cure.
You can support them in the cause by donating here.
The Alliance is the nation’s leading nonprofit dedicated to ending colorectal cancer. Through programs to screen, care, and cure this disease, we will end this disease in our lifetime.
Top resources

In Shawn’s corner: Stepping into the ring to end CRC
Shawn has lived with Crohn’s disease since age 10, a condition that raises his risk of colorectal cancer. He’s stepping into the ring with Haymakers for Hope to help end this disease, and he wants you in his corner.

FDA approves immunotherapy for MSI-H/dMMR stage II & III rectal cancer
The U.S. Food and Drug Administration approved dostarlimab (brand name Jemperli) as the first and only immunotherapy for adults with stage II or III rectal cancer that has a biomarker called MSI-H or dMMR.

Jenny Trefzger: "My missed expiration date"
Jenny Trefzger was 23 when gender-affirming care found her colon cancer. Nine years later, she wants readers to know that you don't have to be extraordinary to beat cancer.




